This month marks 10 years since Blueprint Medicines began operations, and it’s a natural time to celebrate the science, patients and people who have made our work possible. After a transformational year in 2020 – including four product approvals in the United States and Europe, and the advancement of key early-stage research programs to development candidate status – we’ve set an important foundation to accelerate the global reach of our approved therapies, and bring forward our next wave of precision medicines.
Blueprint Medicines’ leadership in precision therapy inspired me to join the company last fall. Since then, I’ve seen our team embody scientific and clinical excellence every day. At our core, we pride ourselves on designing highly potent and selective molecules against difficult-to-drug targets. This approach, combined with our Patients First mindset, positions us well in our efforts to realize the promise of precision medicine.
Our 10th anniversary coincides with this month’s American Association for Cancer Research (AACR) Annual Meeting. At this congress, we reported seven presentations featuring foundational preclinical data for multiple research programs, including EGFR-driven lung cancer, cyclin E-aberrant cancers and cancer immunotherapy, as well as robust clinical data from our systemic mastocytosis programs. We look forward to continuing to apply our productive research platform to bring forward precision therapies that may transform treatment across broad patient populations.
In the future, we will remain focused on the goal of rapidly advancing precision therapies in defined patient populations most likely to benefit. We will seek to identify new opportunities to help patients and apply our expertise to the unique challenges of disease, including the ability to overcome or prevent treatment resistance. We will look to broaden our scientific expertise to additional targets and modalities. In everything we do, we will continue applying our foundational research capabilities: designing highly selective therapies against compelling drivers of disease.
In the video below, my Blue Crew colleagues reflect on our company’s history, recognize our 10-year anniversary and share their views on the future of Blueprint Medicines: